Unknown

Dataset Information

0

CD86 regulates myeloma cell survival.


ABSTRACT: Although prognosis for patients with multiple myeloma has improved over the past decade, research toward discovery of new therapeutic avenues is important and could lead to a cure for this plasma cell malignancy. Here we show that blocking the CD28-CD86 pathway via silencing of either CD28 or CD86 leads to myeloma cell death. Inhibiting this pathway leads to downregulation of integrins and IRF4, a known myeloma survival factor. Our data also indicate that CD86, the canonical ligand in this pathway, has prosurvival activity that is dependent on its cytosolic domain. These findings indicate that targeting of this pathway is a promising therapeutic avenue for myeloma, because it leads to modulation of different processes important in cell viability.

SUBMITTER: Gavile CM 

PROVIDER: S-EPMC5729629 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


Although prognosis for patients with multiple myeloma has improved over the past decade, research toward discovery of new therapeutic avenues is important and could lead to a cure for this plasma cell malignancy. Here we show that blocking the CD28-CD86 pathway via silencing of either CD28 or CD86 leads to myeloma cell death. Inhibiting this pathway leads to downregulation of integrins and IRF4, a known myeloma survival factor. Our data also indicate that CD86, the canonical ligand in this pathw  ...[more]

Similar Datasets

2017-01-01 | GSE89511 | GEO
2014-07-16 | E-GEOD-59424 | biostudies-arrayexpress
| S-EPMC5586597 | biostudies-literature
| S-EPMC7827005 | biostudies-literature
2014-07-16 | GSE59424 | GEO
| S-EPMC4728406 | biostudies-literature
| S-EPMC2773489 | biostudies-other
| S-EPMC3974985 | biostudies-other
| S-EPMC6726976 | biostudies-literature
| S-EPMC11318075 | biostudies-literature